Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Buprenorphine depot - Alar Pharmaceuticals

Next Previous
Drug Profile

Buprenorphine depot - Alar Pharmaceuticals

Alternative Names: ALA-1000; Depot buprenorphine formulation - Alar Pharmaceuticals; INDV-6001

Latest Information Update: 22 Oct 2024

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Alar Pharmaceuticals
  • Class Cyclopropanes; Drug withdrawal therapies; Morphinans; Opioid analgesics; Small molecules
  • Mechanism of Action Nociceptin receptor agonists; Opioid delta receptor agonists; Opioid kappa receptor antagonists; Opioid mu receptor agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No
  • Available For Licensing Yes

Highest Development Phases

  • Phase II Opioid-related disorders; Pain

Most Recent Events

  • 17 Sep 2024 Indivior initiates a phase II trial in Opioid-related disorders (Treatment-experienced) in USA (SC) (NCT06576843)
  • 02 Sep 2024 Indivior plans a phase II trial for Opioid-related disorders (SC) in September 2024 (NCT06576843)
  • 13 Oct 2023 Phase-II clinical trials in Pain in USA (SC) before October 2023 (Alar Pharmaceuticals pipeline, October 2023)

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top